NCT05190523 - Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 6, 2022

Primary Completion Date

March 13, 2024

Study Completion Date

March 13, 2024

Conditions

Primary Biliary Cholangitis

Interventions

DRUG

ASC42 5 mg

5 mg of ASC42 tablets orally once daily for 12 weeks.

DRUG

ASC42 10 mg

2 x 5 mg of ASC42 tablets orally once daily for 12 weeks.

DRUG

ASC42 15 mg

15 mg of ASC42 tablets orally once daily for 12 weeks.

DRUG

Placebo

Placebo tablets orally once daily for 12 weeks.

Trial Locations (1)

Beijing Friendship Hospital, Capital Medical University, Beijing